Malfunctioning sufentanil intrathecal pain pump: a case report
Lindsay Warner1, Anna Branstad2, Lindsay Hunter Guevara3
1Department of Anesthesiology, Mayo Clinic, 200 1st SW, Rochester, MN, 55902, USA. warner.lindsay@mayo.edu.
Journal of Medical Case Reports
|January 5, 2020
Summary
Sufentanil, an opioid rarely used in intrathecal pumps, was administered to a chronic pain patient. Despite a significant underdosing due to pump malfunction, the patient experienced minimal withdrawal, highlighting sufentanil
Area of Science:
- Pain Management
- Pharmacokinetics
- Neurosurgery
Background:
- Sufentanil, a potent opioid, is infrequently utilized for pain management.
- Intrathecal pain pump systems rarely employ sufentanil for drug delivery.
Observation:
- A case report details intrathecal sufentanil use in a 50-year-old male for chronic pain.
- The patient's intrathecal drug delivery system malfunctioned, delivering only 1/100th of the intended sufentanil dosage.
- Notably, the patient did not exhibit significant opioid withdrawal symptoms despite severe underdosing.
Findings:
- The unusual pharmacokinetics of sufentanil, including its lipophilicity and context-sensitive half-times, may explain the lack of major withdrawal.
- This case highlights the complex interplay between drug properties and delivery system function in patient outcomes.
Implications:
- Clinicians should recognize the unique pharmacokinetic profile of sufentanil when considering intrathecal administration.
- Awareness of potential intrathecal drug delivery system malfunctions and their impact on patient response is crucial.
- Understanding these factors is essential for managing patients on intrathecal opioid therapy.
